scholarly journals Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study

2021 ◽  
Author(s):  
Rebecca Cheng ◽  
Kayla Scippa ◽  
Frederick L. Locke ◽  
Julia Thornton Snider ◽  
Heather Jim
Keyword(s):  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Health Related Quality ◽  
T Cell Therapy ◽  
Large B Cell Lymphoma ◽  
Car T Cell Therapy ◽  
Car T ◽  
Related Quality ◽  
Health Related

PCN211 Health-Related Quality of Life in DLBCL Patients Treated with CAR T-Cell Therapy:

2021 ◽  
Vol 24 ◽  
pp. S59
Author(s):  
R. Cheng ◽  
K. Scippa ◽  
F.L. Locke ◽  
J. Cole ◽  
J. Snider ◽  
...  
Keyword(s):  
Quality Of Life ◽  
T Cell ◽  
Cell Therapy ◽  
Health Related Quality ◽  
T Cell Therapy ◽  
Car T Cell Therapy ◽  
Car T ◽  
Related Quality ◽  
Health Related

scholarly journals Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

2021 ◽  
Author(s):  
Jatin Shah ◽  
Sharon Shacham ◽  
Michael Kauffman ◽  
Patrick Daniele ◽  
Dimitrios Tomaras ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Health Related Quality ◽  
Five Dimensions ◽  
Large B Cell Lymphoma ◽  
Related Quality ◽  
Health Related ◽  
Large B Cell

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.

Sign in / Sign up

Export Citation Format

Share Document